Wilder-Smith A - Search Results

1

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J. Vannice KS, et al. Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7. Vaccine. 2018. PMID: 29525283 Free PMC article.

2

Immune correlates of protection for dengue: State of the art and research agenda.

Katzelnick LC, Harris E; Participants in the Summit on Dengue Immune Correlates of Protection. Katzelnick LC, et al. Vaccine. 2017 Aug 24;35(36):4659-4669. doi: 10.1016/j.vaccine.2017.07.045. Epub 2017 Jul 28. Vaccine. 2017. PMID: 28757058 Free PMC article.

3

Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates.

Vannice KS, Cassetti MC, Eisinger RW, Hombach J, Knezevic I, Marston HD, Wilder-Smith A, Cavaleri M, Krause PR. Vannice KS, et al. Vaccine. 2019 Feb 4;37(6):863-868. doi: 10.1016/j.vaccine.2018.12.040. Epub 2019 Jan 11. Vaccine. 2019. PMID: 30639461 Free PMC article.

4

Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine.

Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T. Wilder-Smith A, et al. J Infect Dis. 2016 Dec 15;214(12):1796-1799. doi: 10.1093/infdis/jiw341. Epub 2016 Aug 5. J Infect Dis. 2016. PMID: 27496977 No abstract available.

5

An update on Zika vaccine developments.

Durbin A, Wilder-Smith A. Durbin A, et al. Expert Rev Vaccines. 2017 Aug;16(8):781-787. doi: 10.1080/14760584.2017.1345309. Expert Rev Vaccines. 2017. PMID: 28633549 Free article. Review.

6

Zika vaccines and therapeutics: landscape analysis and challenges ahead.

Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP. Wilder-Smith A, et al. BMC Med. 2018 Jun 6;16(1):84. doi: 10.1186/s12916-018-1067-x. BMC Med. 2018. PMID: 29871628 Free PMC article.

7

Fractional-Dose Yellow Fever Vaccination - Advancing the Evidence Base.

Vannice K, Wilder-Smith A, Hombach J. Vannice K, et al. N Engl J Med. 2018 Aug 16;379(7):603-605. doi: 10.1056/NEJMp1803433. Epub 2018 Jul 11. N Engl J Med. 2018. PMID: 29995585 Free article. No abstract available.

8

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.

Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, Novaes HM, Ng LC, Smith PG, Tharmaphornpilas P, Yoon IK, Cravioto A, Farrar J, Nolan TM. Wilder-Smith A, et al. Lancet Infect Dis. 2019 Jan;19(1):e31-e38. doi: 10.1016/S1473-3099(18)30494-8. Epub 2018 Sep 5. Lancet Infect Dis. 2019. PMID: 30195995 Review.

9

Long-Term Protection After Fractional-Dose Yellow Fever Vaccination.

Wilder-Smith A, Barrett A, Vannice K, Hombach J. Wilder-Smith A, et al. Ann Intern Med. 2019 Jul 16;171(2):145-146. doi: 10.7326/L19-0196. Ann Intern Med. 2019. PMID: 31307078 No abstract available.

10

Misguided approach to dengue vaccine risk.

Wilder-Smith A, Hombach J, Cravioto A. Wilder-Smith A, et al. Science. 2019 Nov 29;366(6469):1082-1083. doi: 10.1126/science.aaz6159. Science. 2019. PMID: 31780549 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

409 results

Search Page

Filters